| 产品描述: | BAY-707 是 MTH1(NUDT1) 的底物竞争性,高效选择性抑制剂,IC50 值 为 2.3 nM。 BAY-707 与其他 MTH1 化合物相比具有良好的药代动力学特征,并且在小鼠中具有良好的耐受性,但实验明显缺乏体外或体内抗癌功效。 |
| 靶点: |
IC50:2.3 nM (MTH1/NUDT1) |
| 体外研究: |
BAY-707 demonstrates a superior cellular target engagement with an EC50 of 7.6 nM, in agreement with its higher enzymatic potency (IC50=2.3 nM). BAY-707 demonstrates a high cell permeability cell permeability in the Caco-2 assay with a efflux ratio of 288 nm/s. BAY-707 shows an overall favorable physicochemical profile and promising in vitro pharmacokinetic properties with high metabolic stability in both human microsomes(0.29L/h/kg,Fmax=78%) and rat hepatocytes (0.54L/h/kg,Fmax=87%). BAY-707 (0-30 μM; 24 hours) has no antiproliferative effects in HMEC, HeLa and SW-480 cells. |
| 体内研究: |
Bay-077 (orally adminstation; 50-250 mg/kg; 2 weeks) exhibits superior biochemical potency, cellular target engagement, and a pharmacokinetic profile to other MTH1 tool compounds, But Bay-077 exerts no anticancer efficacy either in mono- or in combination therapies in CT26 and NCI-H460 mice model. BAY-707 (orally adminstation; 50-250 mg/kg; 2 weeks) is well-tolerated in nude mice, after 7-days treatment, body weight loss does not exceed 10%. |
| 参考文献: |
1. Ellermann M, et al. Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target.ACS Chem Biol. 2017 Aug 18;12(8):1986-1992. |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.468 ml |
17.341 ml |
34.681 ml |
| 5 mM |
0.694 ml |
3.468 ml |
6.936 ml |
| 10 mM |
0.347 ml |
1.734 ml |
3.468 ml |
| 50 mM |
0.069 ml |
0.347 ml |
0.694 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |